Korea Pharmaceutical and Biotechnology Association Launches Collective Learning-Based New Drug Development Project
On the 17th, the Korea Pharmaceutical and Biotechnology Association held an opening ceremony for the Association’s ‘Collective Learning-Based New Drug Development Acceleration Project Group (K-MELLODDY Project Group)’. The Korea Pharmaceutical and Biotechnology Society (Chairman Noh Yeon-hong) announced on the 17th that it is holding an opening ceremony for the ‘Learning-Based New Drug Development Acceleration Project […]
Study Finds Limited Effectiveness of Antibiotics in Bacterial Respiratory Infections
Research findings have shown that the effectiveness of antibiotic use is limited even in bacterial infections of the lower respiratory tract, where bacteria are the main cause. Antibiotic treatment has been considered effective for bacterial infections, as opposed to viral infections, but the new study identified no significant differences in the severity or duration of […]
Study Shows Resolving Dyslipidemia in Childhood Lowers Cardiovascular Disease Risk
One study showed that although dyslipidemia occurs in children and adolescents, if it is resolved before adulthood, the risk of cardiovascular disease becomes similar to that of normal people. Results from a study of non-HDL cholesterol (non-HDL-C) levels and cardiovascular disease (CVD) events from childhood to adulthood led by Dr. Fei Tong Wu of the […]
Treating Dyslipidemia in Childhood Reduces Cardiovascular Disease Risk: Study
One study showed that although dyslipidemia occurs in children and adolescents, if it is resolved before adulthood, the risk of cardiovascular disease becomes similar to that of normal people. Results from a study of non-HDL cholesterol (non-HDL-C) levels and cardiovascular disease (CVD) events from childhood to adulthood led by Dr. Fei Tong Wu of the […]
The World Health Organization (WHO) Revises Strategy Against Hepatitis B – Lowering Treatment Thresholds to Increase Access
The World Health Organization (WHO) has revised its strategy against hepatitis B (HBV). The threshold for treatment has been lowered by dramatically relaxing the medical standards for which treatment is deemed necessary. In other words, it is recognized that it is impossible to end hepatitis without increasing the number of patients receiving treatment. Not only […]
Expanding Treatment Eligibility: WHO’s Revised Strategy Against Hepatitis B
The World Health Organization (WHO) has revised its strategy against hepatitis B (HBV). The threshold for treatment has been lowered by dramatically relaxing the medical standards for which treatment is deemed necessary. In other words, it is recognized that it is impossible to end hepatitis without increasing the number of patients receiving treatment. Not only […]
Breakthroughs in Dyslipidemia Treatment: Promising New Drug Candidates Revealed at ACC.24
#74% reduction in triglyceride levels (floxasiran)#Reduce neutral fat levels by half (olesarsen)#Reduction of LDL cholesterol level by more than half (Rerodalcibef) During the American College of Cardiology’s annual scientific session (ACC.24), new drug candidates considered the next generation of dyslipidemia were revealed. In patients with severely elevated triglyceride levels, flozasiran reduced triglyceride levels by an […]
New Multidisciplinary Approach for Tuberculous Pericarditis Diagnosis and Treatment: A Breakthrough Study
The results of successful diagnosis and treatment of tuberculous pericarditis using a new multidisciplinary approach have been published in an international academic journal. The research team led by Professors Mihyang Jeong (corresponding author) of the Department of Cardiovascular Medicine and Juhyeon Oh (co-first author) of the Department of Nuclear Medicine of the Cardiocerebrovascular Hospital, Seoul […]
Next-Generation Dyslipidemia Drugs Show Significant Reduction in Lipid Levels at ACC.24 Conference
#74% reduction in triglyceride levels (floxasiran)#Reduce neutral fat levels by half (olesarsen)#Reduction of LDL cholesterol level by more than half (Rerodalcibef) During the American College of Cardiology’s annual scientific session (ACC.24), new drug candidates considered the next generation of dyslipidemia were revealed. In patients with severely elevated triglyceride levels, flozasiran reduced triglyceride levels by an […]
Long-Term Follow-Up Results of PSA Testing for Prostate Cancer: Controversy Persists
While controversy continues over the effectiveness of the prostate-specific antigen (PSA) test for detecting prostate cancer, long-term follow-up results over 15 years have been only half successful. Although a decrease in mortality was observed in PSA testers, there was little difference in the absolute number of deaths, so controversy over its effectiveness is expected to […]
